Testicular immunoreactive arginine vasopressin (irAVP) has been shown to inhibit testosterone production by the Leydig cell in vitro. We studied pre- and postpubertal rats and the results are in agreement with the notion that such inhibition might occur in vivo and, therefore, could have physiological significance. Testicular irAVP and serum testosterone levels were measured in 14-, 21-, 28-, 35-, 42-, and 70-day-old rats. The testicular irAVP concentration was lowest in early prepubertal rats, increased significantly to the highest level at 35 days, then decreased at 42 days, and plateaued at 70 days of age. A pubertal increase in serum testosterone was observed at 42 days when AVP was decreasing. Thus, an inverse relationship was observed at the onset of pubertal maturation. These parameters were also measured in 3 groups of rats 1 week after hemicastration which was performed at the ages of 28, 35 and 70 days. In the 28-day-old rats there was a significant decrease in irAVP 1 week later, in contrast to the intact animal, whereas hemicastration performed at 35 and 70 days of age had no impact on irAVP. Our data suggest that the role of AVP may be physiologically relevant during the peripubertal period of testicular maturation in the rat.

Keywords:
Arginine vasopressin, Immature rat, Hemicastration
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.